pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Anti-inflammatory · news · pharmadog
← back to Anti-inflammatory
News mentioning Anti-inflammatory
40
stories
2d
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
3d
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
biopharma dive
4d
5 acquisitions that forced Big Pharmas to co-parent
biospace
14d
STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
stat
17d
Rezera revs up for $181M IPO to fund phase 3 trial of NLRP3 inhibitor
fiercebiotech
18d
Sanofi stops development of Nurix-partnered immune drug
biopharma dive
18d
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
biospace
18d
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
biospace
18d
AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
fiercebiotech
26d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
Oct 22, 26
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
biospace
Oct 22, 26
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
biospace
Oct 22, 26
Rebranded NodThera plans IPO to fund NLRP3 inhibitor’s push toward approval
fiercebiotech
Oct 21, 26
Roivant, continuing ascent, claims another victory for rare disease drug
biopharma dive
Oct 9, 26
TRex Bio prices $117M IPO to support immune drug work
biopharma dive
Oct 5, 26
CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential
biospace
Sep 30, 26
Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal
fiercebiotech
Sep 24, 26
Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution
stat
Sep 22, 26
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
Sep 9, 26
NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
endpoints
Aug 27, 26
New data could widen use of AstraZeneca, Amgen immune disease drug
biopharma dive
Aug 27, 26
Generate Bio drops as data accidentally leaked ahead of European conference
biospace
Aug 27, 26
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
biospace
Aug 25, 26
China’s Haisco forms immunology biotech with up to $1.5B from American VCs
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 10, 26
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
fiercebiotech
Aug 6, 26
BioVie shares halve on murky Parkinson’s disease readout
biospace
Jul 31, 26
Novo Nordisk rocked by late-stage cardiovascular drug failure
endpoints
Jul 31, 26
STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
stat
← prev
page 1 of 2
next →